Company Profile

Acacia Biosciences Inc
Profile last edited on: 3/29/17      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4138 Lakeside Drive
Richmond, CA 94806
   (510) 669-2330
Location: Single
Congr. District: 11
County: Contra Costa

Public Profile

In 1999, Acacia Biosciences was acquired by Rosetta Inpharmatics, itself a wholly owned subsiduary of Merck Pharmaceuticals. Acacia Biosciences is a drug discovery technology company committed to the creation of proprietary assay systems and databases that facilitate the rapid development of biopharmaceutical sand agricultural chemicals. The Genome Reporter Matrix is the first in a series of novel tools that provide practical analysis of early stage chemicals by interpreting their effects across entire genomes. In addition to the GRM, Acacia's technology is used to discover novel targets and gene regulatory mechanisms.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1998 1 NIH $100,000
Project Title: Development Of Novel Antifungal Drug Discovery Tool
1998 1 NIH $100,000
Project Title: Caax Protease Rcelp As An Anticancer Target
1998 1 NIH $100,000
Project Title: Gene Response Profiles Of Human Therapeutics
1998 1 NIH $140,000
Project Title: Discovering The Functions Of Human Genes
1998 1 NIH $140,000
Project Title: Comprehensive Analysis Of Gene Function

Key People / Management

  Laurie Issel-Tarver

  John W Phillips

  Darren H Wong